<DOC>
	<DOCNO>NCT00005796</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Inserting specific gene person 's peripheral stem cell may improve body 's ability fight cancer make cancer sensitive chemotherapy . PURPOSE : Phase I trial study effectiveness combination chemotherapy plus gene therapy treat patient CNS tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Gene Therapy Treating Patients With CNS Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity ( detection replication competent retrovirus ) associate CD34+ cell transduce retroviral vector express human O6-methylguanine DNA methyltransferase adult pediatric patient poor prognosis CNS tumor . II . Determine safety genetic modification cell carry presence ( ex vivo ) recombinant fibronectin ( FN ) fragment utilized assist retroviral entry mammalian cell . III . Determine evidence engraftment cell expose FN retroviral transduction . IV . Determine evidence antibody FN follow infusion cell expose FN ex vivo retroviral transduction . OUTLINE : Patients surgically approachable lesion undergo maximal surgical debulking allow preservation good neurologic functioning . Harvest : Patients receive filgrastim ( G-CSF ) subcutaneously IV begin 4 day prior initiation first leukapheresis continue completion harvest . Peripheral blood stem cell harvest select CD34+ cell transduce fibronectin assisted retroviral vector express human O6-methylguanine DNA methyltransferase . Intensification : Patients receive oral lomustine vincristine IV day 0 oral procarbazine day 1-7 . Treatment repeat every 4 week 4 course absence disease progression unacceptable toxicity . Patients newly diagnose tumor may undergo involved field radiotherapy ( IF-RT ) completion third course chemotherapy may begin fourth course chemotherapy completion IF-RT . Transplantation : Two-thirds transduce CD34+ cell reinfused day 9 first course chemotherapy . The remain portion ( one-third ) transduce CD34+ cell reinfused day 9 second course chemotherapy . Untransduced CD34+ cell reinfused day 9 last 3 course chemotherapy . Patients follow every 3 month 6 month , every 4 month 1 year , every 6 month year 5 , annually thereafter . PROJECTED ACCRUAL : Approximately 15-20 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove newly diagnose CNS tumor Eligible tumor type : Glioblastoma multiforme ( WHO grade IV ) Anaplastic astrocytoma ( WHO grade III ) Anaplastic oligodendroglioma ( WHO grade III ) Mixed anaplastic oligoastrocytoma ( WHO grade III ) Incompletely resect ependymoma Diffusely intrinsic pontine medullary glioma Histology requirement waive OR Histologically proven recurrent progressive CNS tumor Eligible tumor type : Same plus oligodendroglioma ( WHO grade II ) No brainstem tumor arise cervicomedullary region midbrain without histologic proof malignancy No supratentorial low grade astrocytomas ( WHO grade I II ) PATIENT CHARACTERISTICS : Age : 5 Performance status : ECOG 02 Life expectancy : At least 2 month Hematopoietic : Absolute neutrophil count great 1,000/mm3 Platelet count great 100,000/mm3 ( transfusion independent ) Hemoglobin great 10 g/dL time pulmonary function test Hepatic : Bilirubin le 1.2 mg/dL SGOT SGPT less 3 time normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance radioisotope GFR great 70 mL/min Pulmonary : FEV1 , FVC , and/or DLCO great 60 % predict Children uncooperative pulmonary function test must follow : No evidence dyspnea rest No exercise intolerance Oxygen saturation ( pulse oximetry ) great 94 % room air Other : Minimum weight 10 kg Not pregnant nursing No active infection PRIOR CONCURRENT THERAPY : Biologic therapy : No growth factor completion study chemotherapy Chemotherapy : No prior nitrosourea procarbazine Endocrine therapy : No concurrent dexamethasone antiemetic Radiotherapy : No prior craniospinal radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>bone marrow suppression</keyword>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>